Neonatal screening is a vital health programme carried out shortly after birth. It is designed to detect serious congenital conditions early, allowing for prompt intervention and treatment. The goal is to prevent life-threatening complications, reduce long-term damage, and improve the overall health and quality of life of newborn babies.
On this page:
How does Neonatal Screening work?
Why is Neonatal Screening performed?
How does Neonatal Screening work?
Between 48 and 96 hours after birth, a small blood sample is taken from the baby — a procedure commonly known as the heel-prick test. This is usually performed in hospital, but for home births or outpatient deliveries, a midwife or GP will take the sample.
A few drops of blood are collected on a special filter-paper card and sent to a laboratory for testing. The sample is analysed for several serious metabolic and genetic conditions, including phenylketonuria (PKU) and tyrosinaemia (TYR I).
If an abnormal result is found, the doctor listed on the screening card will contact parents to explain the results and discuss the next steps. Early detection and treatment are essential to prevent serious or long-term complications.
What is a PKU Screening Test?
The PKU Screening Test is one of several conditions included in neonatal screening. Phenylketonuria (PKU) is a rare inherited metabolic disorder in which the body cannot properly break down the amino acid phenylalanine.
Without treatment, phenylalanine builds up to toxic levels in the blood, potentially leading neurological and health problems. Early diagnosis through newborn screening allows timely dietary treatment, which helps prevent complications and supports healthy development.
Why is Neonatal Screening performed?
The main purpose of neonatal screening is the early detection of serious health conditions that are not visible at birth but can cause severe complications if not treated quickly.
Neonatal screening is a national public-health programme offered to all newborns and funded by the government. It is free of charge for parents and requires parental consent.
Participation is strongly recommended, as early diagnosis and treatment can significantly improve long-term outcomes for affected infants.
Conclusion
Neonatal screening plays a crucial role in the early detection and treatment of congenital and metabolic disorders. Through ongoing education, research, and policy development, these screening programmes continue to improve, giving more children the best possible start in life.
